Cancer Immunotherapy

Two-Stage Approach Achieves 20-Fold Uptake Of Chemotherapeutic

Published in Immunotherapy Weekly, May 16th, 2001

Immunomedics, Inc. (IMMU) presented results May 2, 2001, on a new method for improved targeting of drugs and isotopes to cancers.

Dr. David M. Goldenberg, Immunomedics, described progress being made in collaboration with its affiliated company, IBC Pharmaceuticals, LLC (IBC), with the next-generation method of pretargeting involving bispecific, or two-armed, antibodies. IBC has broad patent coverage for the pretargeting methodology, referred to as Affinity Enhancement System, or AES, in the scientific literature.

Goldenberg explained that "conventional methods have involved directly attaching therapeutic drugs or isotopes to antibodies, and these...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2001-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry